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Mutations in CHMP2B cause frontotemporal dementia (FTD) in a large Danish pedigree, which is termed FTD
linked to chromosome 3 (FTD-3), and also in an unrelated familial FTD patient. CHMP2B is a component of
theESCRT-IIIcomplex,whichisrequiredforfunctionofthemultivesicularbody(MVB),anendosomalstructure
that fuses with the lysosome to degrade endocytosed proteins. We report a novel endosomal pathology in
CHMP2B mutation-positive patient brains and also identify and characterize abnormal endosomes in patient
ﬁbroblasts. Functional studies demonstrate a speciﬁc disruption of endosome–lysosome fusion but not
protein sorting by the MVB. We provide evidence for a mechanism for impaired endosome–lysosome fusion
whereby mutant CHMP2B constitutively binds to MVBs and prevents recruitment of proteins necessary for
fusion to occur, such as Rab7. The fusion of endosomes with lysosomes is required for neuronal function
and the data presented therefore suggest a pathogenic mechanism for FTD caused by CHMP2B mutations.
INTRODUCTION
Frontotemporal dementia (FTD) is the third most common
form of primary degenerative dementia, accounting for up to
20% of young onset dementia (1). FTD linked to chromosome
3 (FTD-3) is an autosomal dominant presenile dementia,
associated with a large pedigree originating from the Jutland
region of Denmark (2,3).
Analysis of the Jutland pedigree identiﬁed a disease segre-
gating mutation in CHMP2B (4,5). This G.C transition in
the 5′ acceptor splice site of exon 6 produces two aberrant
transcripts: CHMP2B
Intron5 and CHMP2B
D10 (Fig. 1A). The
proteins predicted from these splice variants are both
C-terminal truncations of 36 amino acids (4). A CHMP2B
nonsense mutation has been found in an unrelated familial
FTD patient (6). This mutation (C493T) predicts replacement
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Q165X)
causing a C-terminal truncation of 49 amino acids (Fig. 1A).
CHMP2B is a component of the endosomal sorting complex
required for transport-III (ESCRT-III), which is involved in
endocytic trafﬁcking of proteins (7). Membrane proteins that
are targeted for degradation are internalized, or endocytosed,
into the cell in vesicles which converge on endosomes. A
subset of endosomes mature to form multivesicular bodies
(MVBs), which are characterized by the presence of intralum-
inal vesicles (ILVs) formed by inward budding of the endoso-
mal membrane. MVBs undergo fusion with lysosomes, where
their contents are degraded. ESCRT proteins, including
CHMP2B, are recruited to the endosomal outer membrane,
where they provide a cellular machinery for the sorting of
proteins destined for degradation into ILVs (8).
Here we report a novel endosomal pathology in FTD-3
patient brains and ﬁbroblast cell lines. Using cellular overex-
pression models and patient ﬁbroblast cell lines, we show
that CHMP2B mutants disrupt a late stage of endosomal traf-
ﬁcking: the fusion of endosomes with lysosomes, while
protein sorting into ILVs is intact. We further demonstrate
that deﬁcient fusion may be due to impaired ability of
CHMP2B
Intron5-positive endosomes to recruit Rab7, a
GTPase required for endosome–lysosome fusion.
RESULTS
Mutant CHMP2B expression in patient brains
We used a quantitative real-time PCR assay to determine the
relative levels of CHMP2B
Intron5 and CHMP2B
D10 compared
with CHMP2B
Wildtype transcripts in the frontal cortex of
three FTD-3 patient brains (Fig. 1B). This analysis showed
that CHMP2B
Intron5 was present at  36% and CHMP2B
D10
at  10% of CHMP2B
Wildtype levels. This suggests that
CHMP2B
Intron5 is present at sufﬁcient levels to play a role
in pathogenesis. As CHMP2B
D10 is expressed at lower
levels than CHMP2B
Intron5 but does not have a greater effect
in the functional assays described below, CHMP2B
Intron5
may be more relevant to the disease process.
Enlarged endosomes in patient brains
We have previously shown that overexpression of
CHMP2B
Intron5 and CHMP2B
Q165X produce enlarged lateendo-
somes in human neuroblastoma cells (6). If this endosomal phe-
notype is relevant to neurodegeneration, we would predict a
similar ﬁnding in brain tissue. Frontal cortex sections from
four FTD-3 patients were immunostained for mannose-6 phos-
phate receptor (M6PR), a marker of late endosomes.
Anti-M6PR labelled large vacuoles in the cytoplasm of cortical
neurons which were also visible by haematoxylin and eosin
staining (Fig. 2). The vacuolar pathology was most abundant
in the deep layers of the cortex. To assess their frequency, we
counted the number of neurons that contained enlarged
M6PR-positive vacuoles per high power ﬁeld of cortical layers
III to V in three FTD-3 brains. There was a range of 0–15
neurons with vacuolar pathology per high power ﬁeld (an area
of 0.249 mm
2) with an average of 2.95 per ﬁeld (average range
2–4.85). We then determined the distribution of vacuolar path-
ology in one FTD-3 brain by examining 14 brain regions
(Table 1). Vacuoles were found in all cortical areas examined,
with the exception of the cerebellar cortex. This is consistent
with the generalized cortical atrophy observed on post-mortem
(9) and with imaging data showing that atrophy is widespread
in the FTD-3 cortex (10,11). The vacuoles were not observed
innon-corticalgreymatterregionssuchasthethalamus,substan-
tia nigra, locus coeruleus and medulla. To determine whether
Figure 1. Mutant CHMP2B transcripts are expressed in patient brain. (A)
Schematic diagram showing CHMP2B
Wildtype and the C-terminal truncations
predicted by expression of the mutant transcripts. Grey indicates conservation
of the wild-type protein, black indicates novel amino acids. Notably
CHMP2B
D10 includes a 29 amino acid C-terminal nonsense sequence. (B)
Quantitative real-time PCR analysis of CHMP2B transcripts in three FTD-3
patient brains. CHMP2B
Intron5 is expressed at  36% and CHMP2B
D10 at
 10% of CHMP2B
Wildtype levels.
Figure 2. Enlarged endosomal phenotype in patient brain. Frontal cortex sec-
tions from FTD-3 (A, B, D, E) and age-matched control brains (C, F). Repre-
sentative images of haematoxylin and eosin staining (H&E, A–C) and
immunohistochemical staining against M6PR (D–F) are shown. Cytoplasmic
vacuoles are visible in frontal cortical neurons of FTD-3 brains only, and these
are positive for M6PR, a marker of late endosomes. Insets show enlargements
of affected neurons. Scale bar ¼ 60 mm.
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three Alzheimer’s disease patients, six familial FTD patients
(four with MAPT mutations, two with GRN mutations), 12
prion disease patients and nine age-matched controls (Sup-
plementary Material, Fig. S1 and Table S1). None of these
cases showed enlarged M6PR-positive vacuoles suggesting
that this pathology is a result of the CHMP2B mutation.
Enlarged endosomes in patient ﬁbroblasts
To investigate whether a similar morphological phenotype was
presentinperipheraltissue,wederivedﬁbroblastcelllinesfrom
patient skin biopsies and immunostained them for CD63 to
visualize late endosomes. Enlarged CD63-positive vesicles
were observed; sometimes one very enlarged structure was
present, or more typically, clusters of enlarged endosomes
wereseenwhencomparedwithage-matchedcontrols(Fig.3A).
Four patient (three FTD-3 patients and the CHMP2B
Q165X
patient) and six age-matched control cell lines were examined
by an investigator blind to conditions. Six hundred cells per
line were counted across three independent experiments, with
cells matched for passage number (Fig. 3B). A signiﬁcantly
greater proportion of patient ﬁbroblast cell lines had enlarged
endosomes when compared with controls (t-test, P , 0.0001).
Examination of the ultrastructure of these enlarged endo-
somes by electron microscopy suggested that they were dys-
morphic MVBs. Unusual vesicular structures present in three
patient cell lines, including the CHMP2B
Q165X patient, were
not seen in age-matched controls (Fig. 4A). These structures
were typically enlarged vacuoles with aberrant membrane
deformation at the periphery, or ILVs which did not ﬁll the
lumen. In contrast, normal MVBs, which were seen in both
patient and control cells, were smaller and packed with
ILVs. Immunolabelling showed that these characteristic struc-
tures were likely to be late endosomes as they were positive
for CD63, which also labelled normal degradative compart-
ments and MVBs in patient and control cells (Fig. 4B).
CHMP2B mutations impair fusion of endosomes
with lysosomes
We next investigated the function of these abnormal endo-
somes. Transfected cells were treated with EGF-488 in the
presence of leupeptin, an inhibitor of lysosomal proteases. A 2 h
chaseperiodwassufﬁcienttodelivermostEGF-488tothelyso-
some, as visualized with anti-LAMP1, where it remained unde-
graded. Therefore, colocalization of EGF-488 with LAMP-1
was taken as a measure of successful endosome–lysosome
fusion(Fig.5A).Fiftycellsfromthreeindependentexperiments
were counted for each condition, and the percentage of
EGF-488 which colocalized with LAMP-1 was measured.
The degree of endosome–lysosome fusion was signiﬁcantly
higher in cells expressing CHMP2B
Wildtype compared with
CHMP2B
Intron5 (t-test, P , 0.0001) or CHMP2B
Q165X (t-test,
P , 0.0001). CHMP2B
Wildtype expressing cells were compar-
able to untransfected cells (Fig. 5B).
Impaired fusion was conﬁrmed by delayed degradation
of EGF and its receptor epidermal growth factor receptor
(EGFR). Tetracycline-inducible HEK-293 cell lines expressing
HA-tagged CHMP2B
Wildtype (Wildtype-293) or CHMP2B
Intron5
(Intron5-293) showed downregulation of EGFR in response to
stimulation with EGF, a process requiring delivery of EGFR
from the MVB to the lysosome. However, this process was
delayed in Intron5-293 cells when compared with Wildtype-293
cells (Fig. 5C and D), also suggesting that fusion is impaired.
Impairment of EGF-488 degradation was also shown in trans-
fected SK-N-SH cells. Levels of cellular EGF, as measured by
ﬂuorescence intensity, were recorded after 30 and 90 min chase
(Fig. 6B). In CHMP2B
Wildtype expressing cells,  90% of the
EGFsignalpresentat30 minwasdegradedat90 min.Incontrast,
in cells expressing CHMP2B
Intron5 or CHMP2B
D10,m u c hl e s s
(25–30%) degradation of EGF was observed. Interestingly,
there was partial colocalization of EGF with CHMP2B
Intron5-
positive compartments at 90 min (Fig. 6A, inset), suggesting
that the failure of degradation may be due to EGF being
trapped in these aberrant compartments.
Sorting of EGFR onto ILVs of MVBs is not affected
by CHMP2B mutations
Given the evidence for disruption of endosome–lysosome
fusion and resultant impaired degradation of EGF and
EGFR, we also tested whether CHMP2B mutants impair the
sorting of EGFR onto the intralumenal vesicles of the MVB,
since the ESCRT-III complex has been implicated in this
process. Undegraded EGFR associated with MVBs may be
internalized normally into these structures or remain unsorted
on the outer endosomal membrane. If retained on the outer
membrane, the signalling domain of EGFR will still be
active in the cytoplasm, allowing the activation of downstream
signalling molecules, such as phosphorylation of ERK1/2.
Sorting onto ILVs will sequester EGFR in the MVB, effec-
tively silencing its downstream signalling (8,12).
EGF-induced phosphorylation of ERK1/2 was not affected
by the expression of CHMP2B
Intron5. Both Wildtype-293 and
Intron5-293 cells showed a rapid peak in phosphorylation
after 5 min, which rapidly returned to baseline levels
(Fig. 7B and C). This suggests that EGF-induced signalling
was silenced in both lines, due to the sequestration of EGFR
in the ILVs. To determine whether EGFR was sequestered
on ILVs in patient tissue, FTD-3 patient ﬁbroblasts and age-
matched control ﬁbroblasts were incubated with 100 ng/ml
EGF and a gold-conjugated anti-EGFR antibody. The
Table 1. Distribution of enlarged vacuoles in FTD-3 patient brain
Brain area Presence of vacuoles
Frontal cortex +
Insula +
Parietal cortex +
Occipital cortex +
Temporal cortex +
Hippocampus +
Basal ganglia 2
Thalamus 2
Substantia nigra 2
Locus coeruleus 2
Raphe nuclei 2
Pons 2
Olive 2
Cerebellar cortex 2
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EGF stimulation and can be used to monitor endosomal traf-
ﬁcking by electron microscopy (13). Sorting of EGFR onto
internal vesicles of both normal and abnormal MVBs was
observed in three patient ﬁbroblasts lines: two FTD-3 patients
and one CHMP2B
Q165X patient (Fig. 7). This suggests that
impaired degradation of EGFR is due to decreased fusion
with lysosomes rather than impaired sorting onto ILVs.
Recruitment of Rab7 onto endosomes is impaired
by expression of mutant CHMP2B
We hypothesised that the impaired fusion of endosomes with
lysosomes may be due to a failure of CHMP2B
Intron5-positive
endosomes to recruit proteins necessary for heterotypic
fusion. Endosome–lysosome fusion requires recruitment of
Rab7, a recognized marker of late, fusion-competent
endosomes (14). SK-N-SH cells were co-transfected with
EGFP-Rab7 and CHMP2B
Wildtype, CHMP2B
Intron5 or
CHMP2B
D10 and then immunostained for CD63 to visualize
late endosomes (Fig. 8A). There was an approximate one-third
reduction in the recruitment of EGFP-Rab7 onto endosomes in
CHMP2B
Intron5 cells (t-test, P , 0.0001) and an approximate
one-quarter reduction in CHMP2B
D10 cells (test, P , 0.001)
when compared with cells expressing CHMP2B
Wildtype. This
assay was repeated using an anti-Rab7 antibody to show
endogenous Rab7 rather than using overexpression (Sup-
plementary Material, Fig. S2). Both CHMP2B
Intron5 and
CHMP2B
D10 cells showed at least a one-third reduction in
recruitment of endogenous Rab7 onto endosomes compared
with CHMP2B
Wildtype cells (t-tests, both P , 0.0001)
(Fig. 8B). There were no signiﬁcant differences when compar-
Figure 3. Enlarged endosomal phenotype in patient ﬁbroblasts. Enlarged endosomal structures are observed at a higher frequency in ﬁbroblast cell lines from
mutation positive patients than in age-matched controls. (A) Representative images of CD63 staining showing enlarged structures and normal endosomal stain-
ing. (B) Blind counts revealed a highly signiﬁcant difference between FTD-3 and control cell lines in the percentage of cells showing the enlarged endosomal
phenotype (P , 0.001). Error bars show the SEM of three independent experiments.
Figure 4. Ultrastructural analysis of patient ﬁbroblasts. (A) Aberrantly formed multivesicular bodies (MVBs) were found in ﬁbroblast cell lines from two FTD-3
patients (b and c) and the Q165X patient (d). In contrast to normal MVBs (a), these were typically enlarged and showed unusual peripheral membrane
deformations or sparsity of ILVs. Scale bar ¼ 100 nm. (B) These aberrant structures were positive for CD63, which also decorated normal MVBs and
heavily decorated lysosomes in patient and control cell lines. (e) Normal MVB from a control cell line; (f) normal lysosome from a control cell line; (g) abnormal
compartments from an FTD-3 cell line. Anti-CD63, 10 nm gold; scale bars ¼ 100 nm.
Human Molecular Genetics, 2010, Vol. 19, No. 11 2231ing between experiments, i.e. CHMP2B
Intron5 or CHMP2B
D10
cells showed a similar reduction in both EGFP-Rab7 and
endogenous Rab7 recruitment (Fig. 8B).
DISCUSSION
We have shown that FTD-speciﬁc CHMP2B mutant proteins
cause enlarged late endosomes and disrupt endosome–
lysosome fusion in cell culture models. Aberrant endosomes
were also observed in patient brains and ﬁbroblasts supporting
the relevance of our in vitro overexpression model. We further
dissect the function of the endocytic pathway to show that
protein sorting is intact, indicating a potential pathogenic
event downstream, at the level of fusion with lysosomes.
Cellular degradation of EGF, which is dependent on endo-
somal trafﬁcking to the lysosome, was signiﬁcantly decreased
within the normal time course of this process. Furthermore, the
amount of EGF reaching the lysosome was signiﬁcantly
reduced even after a 2 h chase. Western blotting analysis
showed delayed degradation of the EGF receptor in response
to EGF stimulation, this effect was marked over 2 h but less
discernible at 3 h, suggesting that this process is impaired
but not completely abrogated.
Sorting of EGFR onto the ILVs of MVBs is not functionally
impaired, as shown by the normal time course of EGF-induced
ERK1/2 activation and the presence of immunogold-labelled
EGFR on the ILVs of abnormal endosomes in patient ﬁbro-
blast cells. Knockdown of the ESCRT-III protein CHMP3
similarly prevents fusion of endosomes and lysosomes but
not the deactivation of EGFR (15). CHMP3 knockdown
cells could sequester EGFR into endosomal structures, even
though they formed fewer ILVs than control cells. Similarly,
abnormal structures present in FTD-3 patient ﬁbroblasts inter-
nalized EGFR despite some abnormal membrane deformation
and sparsity of ILVs within the enlarged lumen. In CHMP5
knockout mice, ILV formation is also intact despite impair-
ment of lysosomal degradation (16). Taken together, this evi-
dence suggests uncoupling of these two processes, and that
some CHMP proteins may act downstream of ILV formation
at the level of endosome–lysosome fusion. ILV formation,
which includes deformation of the outer endosomal membrane
and scission, is driven by the ESCRT-III complex (17–20).
In vitro assays using the yeast homologues of the CHMP
proteins, where one ESCRT-III subunit was omitted at a
time, showed VPS2 (the homologue of CHMP2) to be
unnecessary for both membrane deformation and scission
(20). Instead, Vps2 was shown to be necessary for recruiting
the AAA+ ATPase VPS4, required for disassembly and recy-
cling of ESCRT-III subunits.
The negatively charged C terminus of CHMP proteins
functions as an auto-inhibitory domain, interacting with the
positively charged N terminus to keep the protein in a
‘closed’ conformation which masks the membrane binding
properties of the N terminus (21–24). Deletion of the C termi-
nus would therefore be predicted to produce a constitutively
active protein which is likely to accumulate on endosomal
membranes. Furthermore, the C terminus of CHMP2B is
Figure 5. Delayed fusion of endosomes with lysosomes in CHMP2B mutant cells. (A) SK-N-SH cells were treated with leupeptin to inhibit lysosomal proteases,
followed by feeding of AlexaFluor-488 labelled EGF. Trafﬁcking to the lysosome can be conﬁrmed by co-localization of EGF (green) with the lysosomal marker
LAMP-1 (blue). Co-localization (cyan) of EGF with lysosomes occurs when CHMP2B
Wildtype is expressed (a–d), however when CHMP2B
Intron5 (e–h) or
CHMP2B
Q165X (i–l) is expressed, there is less co-localization, indicating that EGF containing endosomes have not fused with lysosomes. (B)  55% of
EGF is colocalized with LAMP-1 in CHMP2B
Wildtype expressing cells, which is comparable to untransfected cells. In contrast, only 15–20% colocalization
is seen in cells expressing CHMP2B
Intron5 (P , 0.0001) or CHMP2B
Q165X (P , 0.0001). (C) Wildtype-293 and Intron5-293 cells were stimulated with EGF
for 0, 1, 2 or 3 h before lysis and western blotting with antibodies against EGFR and HA-tag. (D) Detected protein was quantitated using ImageJ. EGFR
was corrected against b-actin and the level of EGFR plotted as a percentage of the baseline level (i.e. that at time 0). Wildtype-293 cells, ﬁlled symbols;
Intron5-293 cells unﬁlled symbols; error bars represent the SEM of three experiments.
2232 Human Molecular Genetics, 2010, Vol. 19, No. 11necessary for binding VPS4 (25,26); and CHMP2B truncation
mutants lose this VPS4 binding domain so would be predicted
to fail to dissociate from the endosomal membrane.
Dissociation-incompetent CHMP2B may allow ILVs to form
normally but also sequester other ESCRT-III subunits at the
endosomal membrane so that fewer ILVs can be formed
over time.
We propose a model where the accumulation of constitu-
tively bound CHMP2B on endosomes may render them incap-
able of fusion with lysosomes. This latter process is not well
understood, but it may be necessary for ESCRT-III to dis-
sociate before fusion occurs, and/or the constitutive presence
of ESCRT-III may mean that the endosomal membrane is
unable to recruit factors required for fusion. We demonstrate
impaired recruitment of Rab7 onto endosomes in CHMP2B
mutant cells. This may be relevant to the neurodegenerative
process as mutations in RAB7 cause the motor and sensory
neuropathy Charcot–Marie–Tooth type 2B (27,28). Rab7 is
a GTPase marking fusion-competent MVBs, which is
recruited by the HOPS (homotypic vacuole fusion and
vacuole protein sorting) and CORVET (class C core
vacuole/endosome tethering) complexes (14,29). The pro-
portion of endosomes that recruit Rab7 is reduced by
approximately one-third in CHMP2B mutant cells but not
completely diminished. This may explain why fusion is
decreased and degradation delayed instead of completely abro-
gated. Interestingly, overexpression of EGFP-Rab7 did not
rescue this deﬁcit; the reduction in recruitment was the same
for EGFP-Rab7 and endogenous Rab7. This is consistent
with a model where mutant CHMP2B prevents a proportion
of late endosomes from recruiting Rab7 and a greater
concentration of Rab7 is therefore redundant to these
recruitment-incompetent endosomes.
That cortical neurons are selectively vulnerable in the time
course of disease remains a conundrum; although it may
suggest that these cells are particularly dependent on some
aspectofendosomalfunctionfortheirsurvival.Normaltrafﬁck-
ing of growth factors and their receptors is one possible candi-
date. Here we showed that epidermal growth factor remained
undegraded over the normal time course within
Figure 6. Delayed degradation of EGF in CHMP2B mutant cells. (A) SK-N-SH cells were transiently transfected with CHMP2B
Wildtype (a–f), CHMP2B
Intron5
(g–l) or CHMP2B
D10 (m–r), and used 24 h later for an EGF-488 trafﬁcking assay. Cells were fed 100 ng/ml EGF-488 (green) and ﬁxed at either 30 (left panel)
or 90 min (right panel). Fixed cells were immunostained with an anti-myc antibody to visualize myc-CHMP2B transfected cells (red) and the nuclei counter-
stained with Hoecsht (blue). At 30 min, all cells show punctate localization of EGF-488. In CHMP2B
Wildtype-expressing cells at 90 mins (d–f), the EGF-488
signal is degraded. However, in cells overexpressing CHMP2B
Intron5 (j–l) or CHMP2B
D10 (p–r), the majority of EGF-488 remains undegraded. Insets show
magniﬁcation of EGF-488 colocalizing with CHMP2B
Intron5-positive compartments. Scale bar ¼ 20 mm. (B) LSM 510 Meta software was used to quantify
this effect.  95% EGF-488 is degraded in CHMP2B
Wildtype expressing cells, compared with only 25–35% in cells expressing CHMP2B
Intron5 or
CHMP2B
D10 (t-tests, both P , 0.0001).
Human Molecular Genetics, 2010, Vol. 19, No. 11 2233CHMP2B-positive enlarged compartments which failed to fuse
with lysosomes. However, owing to its rapid sorting into the
ILVs of MVBs, there was no prolongation of EGF signalling.
Whereas EGF is rapidly internalized and activates its down-
stream signalling pathways over a short time course (30),
other neuronal growth factor-receptor complexes, such as
BDNF-TrkB, are known to signal from the endosomal mem-
brane over a longer period (31–33). Therefore, further studies
examining how these signalling endosomes are affected in
neuronal models of CHMP2B mutations will be of great inter-
est. The ESCRT complex is also involved in the endosomal–
lysosomal degradation of neurotransmitter receptors (34,35),
so impairment of receptor homeostasis and excitotoxic insult
is another potential neurotoxic mechanism that could be
mediated by mutant CHMP2B proteins. Finally, studies in
Drosophila have recently shown that mutant CHMP2B can
activate the Toll-like receptor pathway (36): a process which
has been implicated in neurodegeneration (37).
Figure 7. Intralumenal vesicle formation and sequestration of the EGF receptor is intact in CHMP2B mutant cells. (A) FTD-3 and control ﬁbroblast cell lines
were stimulated with 100 ng/ml EGF with anti-EGFR-gold for 2–4 h. EM analysis of control cells showed that EGFR moved onto the internal vesicles of MVBs
(a and b) within this time frame. EGFR was also observed on ILVs within normal MVBs and abnormal structures in two different FTD-3 patients (c–e), and the
Q165X patient (f, g). (c) A relatively normal MVB with peripheral ILVs associated with gold particles; (d, e) Abnormal structures containing unusual mem-
branes, but also ILVs associated with gold particles. (f) Enlarged structures containing membranes and ILVs associated with gold particles. (g) EGFR–gold
is clearly identiﬁable on ILVs in MVBs. Anti-EGFR, 10 nm gold; examples of gold particles indicated by arrows; scale bar ¼ 500 nm. (B) Wildtype-293
and Intron5-293 cells were not stimulated (0) or stimulated with EGF for 5 min and then chased for 5, 10, 30 or 60 min. Western blotting with antibodies
against phosphorylated ERK1/2 and total ERK1/2 (C) was quantitated using LI-COR Odyssey software. Phosphorylated ERK1/2 was corrected against total
ERK1/2 and a time course of ERK1/2 activation was plotted as a percentage of the respective phosphorylation intensities after 5 min of EGF stimulation
and 5 min of chase. Wildtype-293 cells, ﬁlled symbols; Intron5-293 cells unﬁlled symbols; error bars represent the SEM of three experiments.
2234 Human Molecular Genetics, 2010, Vol. 19, No. 11Inthe present study, we havefocusedon endosomal dysfunc-
tion as the human pathology data so far support a major role for
this system in the pathogenesis of FTD-3. It is of great interest
that the endosome–lysosome pathway described here also con-
verges with the autophagosomal degradation pathway (38–40)
andthatother cellular studies ofCHMP2B overexpressionhave
shownadeﬁcitinthefusionofautophagosomeswithlysosomes
(41–43). Basal autophagy is required in neuronal cells to
degrade organelles and long lived proteins which might other-
wise accumulate with deleterious effects for the cell (44,45).
It is likely that both of these highly related processes contribute
to the pathogenesis of FTD-3. It is thought that similar mechan-
isms mediate autophagosome–lysosome and endosome–lyso-
some fusion (reviewed in 29), so data presented here for a
putative role for impaired Rab7 recruitment may also be of rel-
evance to the reported deﬁcits in autophagy.
The ﬁndings presented here strongly support a model where
C-terminal truncations of CHMP2B are pathogenic by a toxic
gain-of-function which disrupts endocytic trafﬁcking, produ-
cing deleterious effects for neuronal cells. Defects in endoso-
mal trafﬁcking have been implicated in a number of
neurodegenerative diseases and the novel phenotypic and
functional assays described here may aid diagnosis and the
eventual screening and development of therapeutics.
MATERIALS AND METHODS
Materials
Antibodies used were: rat anti-HA tag (Roche, 1:500), mouse
anti-CD63 (University of Iowa DSHB, 1:400), mouse
anti-LAMP-1 (University of Iowa DSHB, 1:100),
anti-rat-Alexa Fluor 546 (1:500, Invitrogen), anti-mouse-
Alexa Fluor 546 (1:1000, Invitrogen), anti-mouse Alexa
Fluor 633 (1:500, Invitrogen), anti-M6PR (1:100, Afﬁnity
Bioreagents), 1B5 anti-CD63 (a gift from Prof. Mark Marsh,
UCL, 1:1000). EGF-488 was from Invitrogen. All cell
culture reagents were from Invitrogen and all other reagents
from Sigma-Aldrich unless otherwise stated. Human tissues
were obtained at autopsy with consent for use in research.
This study was approved by the UCL Institute of Neurology
and National Hospital for Neurology and Neurosurgery
Local Research Ethics Committee.
Plasmids
CHMP2B DNA constructs were used as previously described
(6) or were N-terminally tagged with the HA epitope by PCR
and TOPOw subcloned into the pcDNA3.1+ or the
pTREx-DEST30 vectors (Invitrogen), and sequence veriﬁed.
EGFP-Rab7 plasmid was a kind gift from Dr G. Schiavo,
Cancer Research UK.
Cell lines
The SK-N-SH cell line (ECACC) and ﬁbroblast cell lines were
cultured in DMEM-4500 mg/ml glucose, 10% foetal bovine
serum, 2 mML -glutamine, 1 mM sodium pyruvate, 100 U/ml
penicillin and 100 mg/ml streptomycin. The TREx-293TMcell
line (Invitrogen) was additionally cultured with 5 mg/ml
blasticidin. Mixed inducible-stable cell lines were generated
by transfection with HA-tagged CHMP2B
Wildtype or
Figure 8. Impaired recruitment of Rab7 onto endosomes in mutant CHMP2B expressing cells. (A) SK-N-SH cells were co-transfected with EGFP-Rab7 (green),
HA-CHMP2B
Wildtype (a, b), HA-CHMP2B
Intron5 (c, d) or CHMP2B
D10 (e, f) and then immunostained for CD63 to visualise endosomes (red) and HA. All
CD63-positive endosomes within each of 40–50 cells per condition were scored for colocalization of EGFP-Rab7 by an experimenter blind to conditions.
(B) There was a signiﬁcant reduction in the percentage of endosomes that recruited EGFP-Rab7 in cells expressing CHMP2B
Intron5 (P , 0.0001) or
CHMP2B
D10 (P , 0.001). Recruitment of endogenous Rab7 was similarly impaired (P , 0.0001 for both CHMP2B
Intron5 and CHMP2B
D10). Scale bar ¼ 10 mm.
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Intron5 constructs in the pTREx-DEST30 vector using
Lipofectamine2000.Cellswerethenselectedin1 mg/mlgenet-
icin and 5 mg/ml blasticidin. To induce CHMP2B expression,
cells were incubated with 0.1 mg/ml tetracycline for 48 h
prior to assay. Fibroblast cells lines were derived from
forearm skin biopsies, tissue was dissected into small pieces
and cultured in DMEM-4500 mg/ml glucose, 15% foetal calf
serum, 2 mML -glutamine, 50 U/ml penicillin and 50 mg/ml
streptomycin.
Quantiﬁcation of RNA transcripts
RNA was extracted from frozen FTD-3 frontal cortex using
TRIzol (Invitrogen), treated with TURBO DNase (Ambion)
and puriﬁed using an RNAeasy Mini Column (Qiagen).
cDNA was generated using the Omniscript Reverse Transcrip-
tion Kit (Qiagen). Relative levels of each CHMP2B transcript
(Wildtype, Intron5 and D10) were determined using a
CHMP2B Taqman probe for quantitative real-time PCR and
allele-speciﬁc primers (Supplementary Material, Table S2).
Within each sample, the amount of each transcript was deter-
mined by comparing to standard curves and then normalizing
to the level of wild-type CHMP2B.
Western blotting
For the EGFR degradation assay, cells were starved for 1 h in
serum-free medium with 1 mg/ml cyclohexamide, then
100 ng/ml EGF were added for the timepoints indicated. For
the phospho-ERK1/2, cells were starved for 4 h, pulsed with
50 ng/ml EGF for 5 min, washed three times with pre-warmed
PBS and pulsed with serum-free medium for the timepoints
indicated. Cell lysates were western blotted as described pre-
viously (6). Quantitation was with ImageJ (NIH) or LeiCor
Odyssey software.
Immunohistochemistry
Immunohistochemistry on formalin-ﬁxed brain tissue was per-
formed as described previously (46). Haematoxylin and eosin
staining was done with conventional methods using Harris’
haematoxylin.
Immunoﬂuoresence
SK-N-SH cells were transfected with Lipofectamine 2000
(Invitrogen) according to standard protocols. For the
EGF-488 degradation assay, 24 h post-transfection cells were
starved in serum-free DMEM for 30 min, before the addition
of 100 ng/ml EGF-488 (Molecular Probes) for the timepoints
indicated. For the endosome–lysosome fusion assay, 24 h
post-transfection cells were starved in serum-free DMEM
with 100 mM leupeptin (Sigma) for 30 min, before the
addition of 100 ng/ml EGF-488 for 30 min. Cells were then
chased with leupeptin-DMEM containing 100 ng/ml
unlabelled EGF for 2 h. Following any cellular assays, cover-
slips were processed for confocal analysis as previously
described (6). Standard settings were used to allow compari-
sons between cells and between independent experiments.
Fluorescence intensity of 12-bit images was assessed using
the histogram function of LSM Meta, where all pixel values
above background ﬂuorescence were counted. Colocalization
was also assessed using the histogram function; threshold ﬂu-
orescence for each channel was set automatically for the
region of interest. CD63-positive endosomes were scored for
the presence or absence of endogenous Rab7 or EGFP-Rab7
by eye after thresholding all images to the same levels using
Adobe Photoshop. All endosomes were counted within
40–50 cells per condition by an experimenter blind to con-
ditions. For quantiﬁcation of enlarged endosomes in patient
ﬁbroblasts blind counts were performed on 600 cells per line
across three independent experiments using cells matched
for passage number. A ﬁbroblast was scored as having
enlarged endosomes if one or more enlarged endosomes
were present, as determined by eye after examination of
several hundred normal cells to familiarize the counter with
the normal range of endosome sizes. The same researcher per-
formed all the cell counts to ensure consistency.
Electron microscopy
Cells were serum starved for 1 h and then stimulated with
human EGF in the presence of 108 (anti-EGFR) gold for the
speciﬁed length of time. Electron microscopy analysis was
performed as described previously (13).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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